Abstract:Among the various risky complications of liver cirrhosis, refractory ascites is associated with poor survival of cirrhotics and persistently worsens their quality of life (QOL). Major clinical guidelines worldwide define refractory ascites as ascites that cannot be managed by medical therapy either because of a lack of response to maximum doses of diuretics or because patients develop complications related to diuretic therapy that preclude the use of an effective dose of diuretics. Due to the difficulty in receiving a liver transplantation (LT), the ultimate solution for refractory ascites, most cirrhotic patients have selected the palliative therapy such as repeated serial paracentesis, transjugular intrahepatic portosystemic shunt, or peritoneovenous shunt to improve their QOL. During the past several decades, new interventions and methodologies, such as indwelling peritoneal catheter, peritoneal-urinary drainage, and cell-free and concentrated ascites reinfusion therapy, have been introduced. In addition, new medical treatments with vasoconstrictors or vasopressin V2 receptor antagonists have been proposed. Both the benefits and risks of these old and new modalities have been extensively studied in relation to the pathophysiological changes in ascites formation. Although the best solution for refractory ascites is to eliminate hepatic failure either by LT or by causal treatment, the selection of the best palliative therapy for individual patients is of utmost importance, aiming at achieving the longest possible, comfortable life. This review briefly summarizes the changing landscape of variable treatment modalities for cirrhotic patients with refractory ascites, aiming at clarifying their possibilities and limitations. Evolving issues with regard to the impact of gut-derived systemic and local infection on the clinical course of cirrhotic patients have paved the way for the development of a new gut microbiome-based therapeutics. Thus, it should be further investigated whether the early therapeutic approach to gut dysbiosis provides a better solution for the management of cirrhotic ascites.

Clinical Research of Persistent Ascies by Infusing Ultrafitrate Concentration Back into Abdominal Cavity

Nursing Experience of 61 Patients with Hepatic Cirrhosis Treated by Transfusion of Ultrafiltrated and Concentrated Self-Ascites

Outcomes and Economic Evaluation of Patients with Refractory Ascites Treated by Ultrafilter Concentration and Reinfusion

Study of Ascitic-Concentrated Bacteria-Filtered Intravenous Re-Transfusion (ABR) to Treat Patients with Peritonitis of Schistosoma Cirrhosis

Efficiency of Double Plasma Molecular Absorption System on the Acute Severe Cholestatic Hepatitis.

Clinical Observation on Alcoholic Cirrhosis Treated with Method for Dissipating Phlegm and Removing Blood Stasis

41 cases of ascites reinfusion ultrafiltration combined dopamine and furosemide treatment of liver cirrhosis with refractory ascites analysis

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

Study on endotoxin and bilirubin removal by CA/PEI affinity membrane and protein ultrafiltration by polysulfone hollow fiber membrane in ascites of cirrhosis

Double Ascites Ultrafiltration and Reinfusion into Abdominal Cavity of Hepatocirrhosis Patients with Refractory Ascites Combined with Spontaneous Bacterial Peritonitis

Management of refractory cirrhotic ascites: challenges and solutions

Online Ascites Reinfusion Through Extracorporeal Condensing Method in Uremia Patients with Refractory Ascites

Current management of refractory ascites in patients with cirrhosis

Clinical Observation on Continuous Drainage of Abdominal Cavity in the Treatment of Thirty-eight Patients with Refractory Ascites

Comparison of Intermittent Drainage of Ascites and Diuretic Therapy for Cirrhosis Patients with Tense Ascites

Efficacy of Intraperitoneal Catheter Persistent Ascites Drainage in Patients with Hepatorenal Syndrome

Preventive and Treatment Interventions for Abdominal Ascites of Patients with Liver Cirrhosis: A Systematic Review of Randomized Controlled Trials

Effect of ascites ultrafiltration-concentration back-transfusion treatment on the natural killer cells (NKT) and renal-angiotensin II-aldosterone system (RAAS) for patients with cirrhotic refractory ascites

Recent developments in the management of ascites in cirrhosis

Effects of Plasma Exchange Combined with Continuous Renal Replacement Therapy on Acute Fatty Liver of Pregnancy.

[Clinical Research of Plasma Exchange with Continuous Veno-Venous Hemofiltration in Treating Mid- and Late-Stage Chronic Severe Viral Hepatitis B Patients].